Evorpacept is a fusion protein commercialized by ALX Oncology, with a leading Phase III program in Adenocarcinoma Of The Gastroesophageal Junction. According to Globaldata, it is involved in 14 clinical trials, of which 12 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Evorpacept’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Evorpacept is expected to reach an annual total of $500 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
evorpacept is under development for the treatment of advanced solid tumors including colorectal cancer, indolent and aggressive B-cell non-Hodgkin lymphoma, gastro-esophageal junction cancers, acute myeloid leukemia, relapsed or refractory multiple myeloma, relapsed/refractory acute myeloid leukemia, epithelial ovarian, endometrial cancer, urothelial cancers, recurrent head and neck cancer squamous cell carcinoma and relapsed or refractory, higher risk myelodysplastic syndrome, non-Hodgkin lymphoma including mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, metastatic gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma, metastatic transitional (urothelial) tract cancer. It is administered intravenously. The drug candidate is a fusion protein containing high affinity CD47 binding domain of SIRPalpha linked to an inactive Fc region of human immunoglobulin.
It was also under development for breast cancer, leiomyosarcoma, non-small cell lung cancer, pancreatic, peritoneal, appendiceal, thymic cancers.
ALX Oncology Overview
ALX Oncology (ALXO) is an immune-oncology company that discovers and develops treatments for cancer and hematology indications. It is investigating its lead product candidate evorpacept (ALX148), a CD47 blocker for the treatment of hematologic and solid tumors; and ALTA-002, a SIRPa toll-like receptor agonist antibody conjugate (TRAAC) targeting advanced cancer. The company is also evaluating its lead candidate in combination with other agents against head and neck squamous cell carcinoma, gastric, urothelial, and breast cancer, myelodysplastic syndromes, acute myeloid leukemia, and non-Hodgkin’s lymphoma. ALXO is headquartered in South San Francisco, California, the US.
The operating loss of the company was US$127.4 million in FY2022, compared to an operating loss of US$83.6 million in FY2021. The net loss of the company was US$123.5 million in FY2022, compared to a net loss of US$83.5 million in FY2021.
For a complete picture of Evorpacept’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.